

This week in therapeutics

Indication	Target/marker/athway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Tubulin	<p>An SAR study identified a 10-(2-oxo-2-Phenylethylidene)-10<i>H</i>-anthracen-9-one tubulin polymerization inhibitor that may be useful for treating cancer. In a panel of five human or mouse tumor cell lines, the compound inhibited proliferation with IC₅₀ values in the 60–80 nM range. In a second panel that included drug-resistant tumor cell lines, inhibitory activity was preserved with IC₅₀ values of 40–50 nM. Next steps include studying additional 10-(2-oxo-2-Phenylethylidene)-10<i>H</i>-anthracen-9-one analogs and clarifying the mechanism of antimetabolic activity for this class of compounds.</p> <p>SciBX 2(9); doi:10.1038/scibx.2009.350 Published online March 5, 2009</p>	Patent and licensing status unavailable	<p>Prinz, H. <i>et al.</i> <i>J. Med. Chem.</i>; published online Feb. 16, 2009; doi:10.1021/jm801338r Contact: Helge Prinz, Westphalian Wilhelms-University, Münster, Germany e-mail: prinz@uni-muenster.de</p>